Women's Health Archives - Infectious Disease Advisor

pregnant woman with a hand on her belly sitting at a table meeting with a female physician

Placental Injury Observed in Pregnant Women With SARS-CoV-2

June 9, 2020

Higher rates of decidual arteriopathy and other maternal vascular malperfusion features are seen in placentas of women with severe acute respiratory syndrome coronavirus 2.

Sexually Transmitted Diseases

Single-Dose Secnidazole Treats Trichomoniasis in Phase 3 Trial

By

Brian Park, PharmD

May 18, 2020

The multicenter, double-blind, placebo-controlled study investigated the efficacy and safety of secnidazole in 147 adult females with trichomoniasis.

Pediatric Illnesses

During Outbreak, Most Pregnant Women Had High Zika Awareness

May 5, 2020

Pregnant women had a high level of awareness about Zika virus during the 2016 outbreak, according to a study published in the May issue of Emerging Infectious Diseases.

Hepatitis

Universal Testing May Help Identify HCV in Pediatric Population

By

Zahra Masoud

April 24, 2020

New polices, including testing for hepatitis C virus (HCV) during pregnancy, may increase HCV identification in the pediatric population by addressing gaps in maternal HCV testing.

Prevention

USPSTF Against Bacterial Vaginosis Screening to Prevent Preterm Delivery

April 13, 2020

The U.S. Preventive Services Task Force recommends against screening for bacterial vaginosis in pregnant women not at increased preterm delivery risk.

Approximately 50% of people with HIV have dyslipidemia.3 Common lipid disorders in treated or untreated patients are elevated triglyceride levels and decreased levels of total, high-density lipoprotein, and low-density lipoprotein cholesterol.3,8 Studies consistently associate ART with lipid changes, which may be a direct effect of ART or may result from viral suppression.3,6,8,9 Typical onset of dyslipidemia is within 3 months of starting ART.8 The PIs most likely to induce dyslipidemia are lopinavir, ritonavir, fosamprenavir, and tipranavir; whereas, atazanavir and darunavir are less likely to cause dyslipidemia.3 The non-NRTI efavirenz poses a greater risk for dyslipidemia than the non-NRTIs rilpivirine, etravirine, and nevirapine.3 Older NRTIs affected lipid levels adversely but are rarely used, and the newer NRTIs tenofovir and abacavir may even improve lipid levels.3 Raltegravir and dolutegravir are integrase strand transfer inhibitors, which tend to be lipid neutral and are preferred first-line agents.3

HIV/AIDS

Higher Rate of Dyslipidemia Among Women Living With HIV

By

Bradley van Paridon

April 9, 2020

Despite relatively young ages, a significantly greater percentage of women living with HIV had dyslipidemia than did controls.

pregnant woman in doctor office for checkup

COVID19

Addressing COVID-19 Concerns in Pregnant Women With Rheumatic Diseases

By

Meghna Rao

April 9, 2020

In this interview, Jane E Salmon, MD, provides insight into the risk for COVID-19 in pregnant women with rheumatic diseases.

COVID19

Three Neonates Born to Mothers With COVID-19 Identified as Positive

April 1, 2020

Three of 33 neonates born to mothers with coronavirus disease 2019 (COVID-19) in Wuhan tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).